Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, 2:1 Randomised Monocentre Study to Investigate the Efficacy and Safety of Telmisartan (80 mg qd) Concerning the Amelioration of Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients)

NCT00274105 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00274105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00274105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, 2:1 Randomised Monocentre Study to Investigate the Efficacy and Safety of Telmisartan (80 mg qd) Concerning the Amelioration of Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Terminated
Start date
March 1, 2001
Completion date
October 1, 2004
Enrollment
22
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronary arteriosclerosis, hypertension